Protective Effect of Ursodeoxycholic Acid on Liver Function in Pediatric Patients with Seizure Treated with

Khadije Rezaie Keikhaie1, Mohammad Hasan Mohammadi2, Khadijeh Saravani2,3

  • 1Department of Obstetrics and Gynecology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran.

Maedica
|June 2, 2023
PubMed

Insights

Ursodeoxycholic acid may help protect liver function in children treated with phenobarbital for epilepsy. This study suggests it can improve liver enzymes in patients experiencing drug-induced liver injury.

Area of Science:

  • Pediatric Neurology
  • Hepatology
  • Pharmacology

Background:

  • Epilepsy is a prevalent neurological disorder requiring treatment, often with phenobarbital.
  • Phenobarbital treatment can lead to significant liver complications.
  • Identifying strategies to mitigate phenobarbital-induced hepatotoxicity is crucial.

Discussion:

  • Ursodeoxycholic acid demonstrated a beneficial effect on liver enzymes in pediatric patients.
  • The study suggests a protective role for ursodeoxycholic acid against phenobarbital-induced liver injury.
  • Further research is warranted to confirm these findings and establish optimal dosing.

Key Insights:

  • Ursodeoxycholic acid administration improved liver function markers in pediatric patients.
  • The intervention showed a relative effect in ameliorating liver injury caused by phenobarbital.
  • Liver enzyme levels were significantly improved in the ursodeoxycholic acid group compared to placebo.

Outlook:

  • Investigating the long-term efficacy and safety of ursodeoxycholic acid in this context.
  • Exploring the underlying mechanisms of ursodeoxycholic acid's hepatoprotective effects.
  • Evaluating ursodeoxycholic acid as an adjunct therapy for epilepsy patients on phenobarbital.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
699
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
221
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
477
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
928